# Emergence Agitation of Sevoflurane in Pediatric

> **NCT06830564** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 126 (actual)

## Conditions studied

- Emergence Delirium

## Interventions

- **DRUG:** we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure
- **DRUG:** we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure

## Key facts

- **NCT ID:** NCT06830564
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830564, "Emergence Agitation of Sevoflurane in Pediatric". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06830564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*